a Study of Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• ≥18 years old
• histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations.
• predicted life expectancy ≥ 12 weeks.
• patient must have measurable disease according to RECIST 1.1
Locations
Other Locations
China
Fudan university shanghai cancer center
RECRUITING
Shanghai
Contact Information
Primary
Jialei Wang
wangjialei@shca.org.cn
18017312369
Time Frame
Start Date: 2025-02-07
Estimated Completion Date: 2027-05-30
Participants
Target number of participants: 14
Treatments
Experimental: Sunvozertinib 300mg QD
sunvozertinib monotherapy, 300mg QD
Related Therapeutic Areas
Sponsors
Leads: Fudan University